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Development and Large Scale Manufacturing of 
Exosome-Based Therapeutics
Konstantin Konstantinov, Ph.D.
SVP, Manufacturing & Process Sciences
Integrated Continuous Biomanufacturing III Conference
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2Cascais Rio
Beautiful Cascais
32002:  B&B – USP/DSP integration using 
annular chrom (Bayer)
1996:  B&B – large scale continuous 
NS0 process for Mab (Bayer)
1989:  B&B - SCP continuous process 
optimization & control (Osaka U)
1970s:  SCP continuous process 
using methanol (ICI)
2004:  ACS industrial award to Bayer 
for perfusion technology dev
Brief history of my involvement with continuous 
bioprocessing
2012: B&B – Integrated continuous 
biomanufacturing (Genzyme)
2014: Progress with continuous Mab 
production (Genzyme)
2015: Capacity of a fully integrated 
continuous system (Genzyme)
4W. Ross Ashby (1956): An Introduction to Cybernetics
The principle of requisite variety
If a system is to be stable, the number of states of its control mechanism must be 
greater than or equal to the number of states in the system being controlled.
“ …. only variety can destroy variety "
An Expert Approach for Control of Fermentation Processes as Variable Structure Plants.  J. Ferment. Bioeng., 70, 48-57 (1990)
Exosomes:  A new modality with a tremendous therapeutic potential
5Biotherapeutic Modalities and Technologies for Their Manufacturing:  








































6Exosome Science and Bioprocess Engineering 
have evolved independently
Bioprocess Engineering
• Rich experience with MAbs & rProteins
• Upstream/Downstream/Fill-finish
• Cell Culture Engineering
• Protein Recovery
• Analytics & Characterization




• Rapidly advancing, but not yet mature
• Driven by academia (2016 ISEV:  95% 
academic participants)
• Few companies, mostly startups
• No large scale applications
• Tremendous therapeutic potential
Codiak
• Bridge the two fields
• Integrate the best science & 
process technology  
• Hire people from both fields
7Exosomes: A New Biotherapeutic Modality
Introduction to Exosome Biology
Approach to Exosome Manufacturing






Nikki Ross, Codiak BioSciences exosome isolation data
Exosomes:  Next Generation Biologicals
EM image: Purified exosomes from human cells
9Exosome Biology
Subclass of Extracellular Vesicles
Produced by all living cells
Native information carrier between tissues
Protected from the immune system
10
Mechanisms for Exosome Uptake by Cells
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Exosome Terminology Can Be Confusing
• Many “-somes” in the literature
- Exosomes, endosomes, ectosomes, oncosomes, dectosomes, connectosomes, 
gohstosomes, vexosomes, FedExosomes, …
• No standard definition translatable into characterization methods
• Typical exosome attributes
- Size (40~200 nm)
- Canonical surface proteins (CD9, CD47, CD63, CD81, etc.)
- Relevant functional assays (uptake, biodistribution, etc.)
- However, above attributes overlap with other Extracellular Vesicles
12






















Rapidly Growing Number of Exosome Companies
Exosomes: A New Biotherapeutic Modality
Introduction to Exosome Biology






Recent Results and Path Forward
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Challenges in Exosome Manufacturing
• New scientific field, so far driven mostly by academia.  
Low level of maturity and standardization
• Limited analytics & characterization
• Insufficient sample purity complicating data interpretation
• High complexity
• Non-scalable exosome production process
16
Nanoparticle Tracking Analysis (NTA) is used routinely for exosome 
titer & size characterization






















A Typical Current (Academic) Process
Grow adherent cells (typically primary MSCs) in serum
Wash and remove old media, grow cells without serum
2000 g spin, 30 minutes, 4C to remove cells (discard pellet)
12000 g spin, 45 minutes, 4C to remove cell debris (discard pellet)
Dilute supernatant in sucrose cushion
110,000 g spin, 120 minutes, 4C (discard supernatant)
Resuspend pellet and wash in PBS
110,000 g spin, 70 minutes, 4C (discard supernatant)
Perform particle count, freeze in PBS or alternate solutionResuspend pellet and wash in PBS
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The Codiak Exosome Platform
SURFACE ENGINEERING LOADING SPECIFIC PAYLOADS













Integration of Codiak’s Biological and Production Platforms
Static Component (Production Process)
Bioreactor Purification Loading Formulation
Three Variable Components (Cell Lines, Payloads, Delivery Routes)






Exosomes: A New Biotherapeutic Modality
Introduction to Exosome Biology






Recent Results and Path Forward
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Targeting KRAS with siRNA-Loaded Exosomes
PBS Control Exo siKras G12D iExo





































Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar, Valerie S. LeBleu, Hikaru Sugimoto, Sujuan Yang, Carolina F. Ruivo, Sonia A., Melo, J. Jack Lee & Raghu Kalluri
Nature (2017)    doi:10.1038/nature22341, Received 20 September 2016   Accepted 03 April 2017   Published online  07 June 2017
Intra-venous Intra-peritoneal














































































s Building the 
fundamentals
Steady growth
Introduction of Advanced New Technologies
Internet, monoclonal antibody, electric cars, gene therapy, etc. 














To the awesome ICB community -






































and many, many others …
Academia:  Prof. Cooney (MIT),  Prof. Yoshida (Osaka U)
